News

Salt Lake City International Airport’s strong performance can be attributed not only to its punctual flights —84 percent of ...
The Company plans to hold an end-of-Phase 2 Type B meeting with the FDA in the third quarter of 2025. This meeting will review results from the Phase 2 VISIONARY-MS trial and discuss the planned Phase ...